Zymeworks Announces Participation in Upcoming Investor Conferences

Company Overview - Zymeworks Inc. is a clinical-stage biotechnology company focused on developing novel, multifunctional biotherapeutics aimed at improving treatment for difficult-to-treat diseases [2] - The company is committed to making a meaningful difference in the lives of patients affected by challenging cancers and other diseases through its innovative therapeutic platforms [2] Product Development - Zymeworks has engineered zanidatamab, a HER2-targeted bispecific antibody utilizing its proprietary Azymetric™ technology [2] - Zanidatamab is currently undergoing multiple global clinical trials as a potential best-in-class treatment for patients with HER2-expressing cancers [2] - A Biologics License Application (BLA) for zanidatamab has been accepted by the U.S. FDA for accelerated approval as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC) [2] - The BLA has also been accepted for review by the National Medical Products Administration (NMPA) in China, which could lead to zanidatamab being the first HER2-targeted treatment specifically approved for BTC in both the U.S. and China [2] Strategic Partnerships - Zymeworks has entered into agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting them exclusive rights to develop and commercialize zanidatamab in different territories [2] - The company is leveraging its therapeutic platforms through strategic partnerships with global biopharmaceutical companies to enhance its product pipeline [2] Upcoming Events - Zymeworks management will participate in the BTIG Virtual Biotechnology Conference on August 6 and the Wedbush PacGrow Healthcare Conference on August 14, engaging in one-on-one meetings and panel discussions [1][2]